School of Medicine and Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales 2522, Australia; Illawarra Health and Medical Research Institute, Wollongong, New South Wales 2522, Australia.
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13;101:109908. doi: 10.1016/j.pnpbp.2020.109908. Epub 2020 Mar 4.
Major depressive disorder (MDD) is one of the leading causes of years lived with disability and contributor to the burden of disease worldwide. The incidence of MDD has increased by ~20% in the last decade. Currently antidepressant drugs such as the popular selective serotonin reuptake inhibitors (SSRIs) are the leading form of pharmaceutical intervention for the treatment of MDD. SSRIs however, are inefficient in ameliorating depressive symptoms in ~50% of patients and exhibit a prolonged latency of efficacy. Due to the burden of disease, there is an increasing need to understand the neurobiology underpinning MDD and to discover effective treatment strategies. Endogenous models of MDD, such as the Wistar-Kyoto (WKY) rat provide a valuable tool for investigating the pathophysiology of MDD. The WKY rat displays behavioural and neurobiological phenotypes similar to that observed in clinical cases of MDD, as well as resistance to common antidepressants. Specifically, the WKY strain exhibits increased anxiety- and depressive-like behaviours, as well as alterations in Hypothalamic Pituitary Adrenal (HPA) axis, serotonergic, dopaminergic and neurotrophic systems with emerging studies suggesting an involvement of neuroinflammation. More recent investigations have shown evidence for reduced cortical and hippocampal volumes and altered glutamatergic signalling in the WKY strain. Given the growing interest in therapeutics targeting the glutamatergic system, the WKY strain presents itself as a potentially useful tool for screening novel antidepressant drugs and their efficacy against treatment resistant depression. However, despite the sexual dimorphism present in the pathophysiology and aetiology of MDD, sex differences in the WKY model are rarely investigated, with most studies focusing on males. Accordingly, this review highlights what is known regarding sex differences and where further research is needed. Whilst acknowledging that investigation into a range of depression models is required to fully elucidate the underlying mechanisms of MDD, here we review the WKY strain, and its relevance to the clinic.
重度抑郁症(MDD)是导致残疾年数和全球疾病负担的主要原因之一。在过去十年中,MDD 的发病率增加了约 20%。目前,抗抑郁药如流行的选择性 5-羟色胺再摄取抑制剂(SSRIs)是治疗 MDD 的主要药物干预形式。然而,SSRIs 在改善约 50%的患者的抑郁症状方面效率低下,并且表现出疗效的潜伏期延长。由于疾病负担,越来越需要了解 MDD 的神经生物学基础,并发现有效的治疗策略。内源性 MDD 模型,如 Wistar-Kyoto(WKY)大鼠,为研究 MDD 的病理生理学提供了有价值的工具。WKY 大鼠表现出与临床 MDD 病例中观察到的行为和神经生物学表型相似的特征,以及对常见抗抑郁药的耐药性。具体而言,WKY 品系表现出增加的焦虑和抑郁样行为,以及下丘脑-垂体-肾上腺(HPA)轴、5-羟色胺能、多巴胺能和神经营养系统的改变,新兴研究表明其涉及神经炎症。最近的研究表明,WKY 品系的皮质和海马体积减少,以及谷氨酸能信号改变。鉴于人们对靶向谷氨酸能系统的治疗方法越来越感兴趣,WKY 品系本身就是筛选新型抗抑郁药及其对治疗抵抗性抑郁症疗效的潜在有用工具。然而,尽管 MDD 的病理生理学和病因学存在性别二态性,但 WKY 模型中的性别差异很少被研究,大多数研究集中在男性身上。因此,本综述强调了已知的关于性别差异的内容,以及需要进一步研究的地方。虽然承认需要研究一系列抑郁症模型才能充分阐明 MDD 的潜在机制,但我们在此回顾了 WKY 品系及其与临床的相关性。